Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Fineline Cube Jul 16, 2026
Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Fineline Cube Jul 16, 2026
Company Drug

EMA’s CHMP Recommends Approval of Bayer’s Acoramidis for ATTR-CM Treatment

Fineline Cube Dec 16, 2024

Bayer’s (ETR: BAYN) acoramidis has received a positive recommendation from the Committee for Medicinal Products...

Policy / Regulatory

Guangdong Province Releases List of Urgent Clinical Drugs and Devices for GBA Cities

Fineline Cube Dec 16, 2024

The medical products administration and health commission of Guangdong province have released a list of...

Company Drug

Sanofi’s Tolebrutinib Earns FDA Breakthrough Designation for Non-Relapsing Secondary Progressive MS

Fineline Cube Dec 16, 2024

Sanofi (NASDAQ: SNY) has announced that the US Food and Drug Administration (FDA) has granted...

Company Medical Device

Roche’s cobas 6800/8800 Systems 2.0 Earn CE Certification, Set for US Market Entry

Fineline Cube Dec 16, 2024

Global healthcare company Roche (SWX: ROG) has announced that its state-of-the-art cobas 6800/8800 Systems 2.0...

Company Drug

ARS Pharmaceuticals’ Neffy Receives Market Filings in Asia-Pacific Region

Fineline Cube Dec 16, 2024

US-based ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) has announced that market filings for its intranasal epinephrine...

Company Drug

Fujian Cosunter Pharmaceutical’s GST-HG141 Earns Breakthrough Designation for Chronic Hepatitis B

Fineline Cube Dec 16, 2024

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that it...

Policy / Regulatory

Beijing Conference Outlines 2025 Healthcare Security Goals and 2024 Progress

Fineline Cube Dec 16, 2024

A national conference on healthcare security was recently held in Beijing, reviewing the achievements of...

Company Deals

Quantum Hi-Tech (ChemPartner) Plans to Raise Over RMB 930 Million in Private Placement

Fineline Cube Dec 16, 2024

Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), is poised to raise...

Company Deals

AbbVie Acquires Roche’s Nimble Therapeutics to Boost Immunology Pipeline

Fineline Cube Dec 16, 2024

US pharmaceutical company AbbVie (NYSE: ABBV) has reached an agreement to acquire Swiss pharmaceutical giant...

Company Deals

iFlytek’s Xunfei Healthcare Passes HKEX Hearing for AI-Powered Medical IPO

Fineline Cube Dec 16, 2024

Xunfei Healthcare Technology Co., Ltd., a subsidiary of China’s leading information technology company iFlytek Co.,...

Company Deals

Innovent Biologics Partners with Eli Lilly for Distribution of Jaypirca in China

Fineline Cube Dec 16, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has entered into a significant distribution and promotion agreement...

Company Drug

Accropeutics Gets FDA Green Light for Phase II UC Study of RIPK2 Inhibitor AC-101

Fineline Cube Dec 16, 2024

Accropeutics Inc., a clinical-stage biotechnology company with operations in New York, US, and Suzhou, China,...

Company Drug

EMA’s CHMP Supports Approval of Eli Lilly’s Omvoh (Mirikizumab) for Crohn’s Disease

Fineline Cube Dec 16, 2024

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recently...

Company Drug

Wepon Medical’s WP107 for Myasthenia Gravis Accepted for FDA Review

Fineline Cube Dec 16, 2024

Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced that the US Food and...

Company Deals

Mabwell Bioscience Plans Secondary Listing in Hong Kong, Secures Funding for Bone Health Project

Fineline Cube Dec 16, 2024

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) is set to make a secondary listing on...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Lupus Nephritis Clinical Trial

Fineline Cube Dec 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has obtained approval from...

Company Deals

Neusoft Medical Systems and Xiamen University Launch MRI R&D Center Partnership

Fineline Cube Dec 16, 2024

Neusoft Medical Systems Co., Ltd, a prominent Chinese medical technology company, has signed an agreement...

Company Deals

Neusoft Medical Systems and NMPA Collaborate on AI-Enhanced Drug Administration

Fineline Cube Dec 16, 2024

Neusoft Medical Systems Co., Ltd, a leading Chinese medical technology company, has announced a strategic...

Company Drug

Grand Pharmaceutical’s STC3141 Sepsis Therapy Completes Phase II Patient Enrollment

Fineline Cube Dec 16, 2024

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the completion of patient enrollment...

Company Drug

Innovent Biologics Initiates Phase I Trial for IBI3009 in Small Cell Lung Cancer and Neuroendocrine Tumors

Fineline Cube Dec 15, 2024

On December 13, 2024, Innovent Biologics, Inc. (HKG: 1801) registered a Phase I clinical trial...

Posts pagination

1 … 275 276 277 … 695

Recent updates

  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
  • Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy
  • Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity
  • Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia
  • China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma

Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Company Drug

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Company Drug

Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.